News
LPCN
2.560
+1.19%
0.030
Lipocine price target lowered to $6 from $11 at Alliance Global
TipRanks · 2d ago
Weekly Report: what happened at LPCN last week (0406-0410)?
Weekly Report · 3d ago
Insider Move: Lipocine Director Makes Bold New Stock Purchase
TipRanks · 04/08 02:02
Lipocine director John W. Higuchi buys $81,200 common shares
Reuters · 04/07 22:28
Top Lipocine Insiders Make Bold Move With Fresh Share Purchases
TipRanks · 04/07 02:04
Lipocine director John W. Higuchi buys $252,150 common shares
Reuters · 04/06 23:01
Lipocine CEO Mahesh Patel acquires $50,750 common shares
Reuters · 04/06 22:33
What's Going On With Carvana Stock Monday?
Benzinga · 04/06 18:06
What's Going On With Lipocine Stock On Monday?
Benzinga · 04/06 13:09
This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Benzinga · 04/06 12:56
Lipocine Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 04/06 12:16
HC Wainwright & Co. Downgrades Lipocine to Neutral
Benzinga · 04/06 12:06
Lipocine downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 04/06 10:16
LIPOCINE INC <LPCN.O>: H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY
Reuters · 04/06 10:14
Weekly Report: what happened at LPCN last week (0330-0403)?
Weekly Report · 04/06 10:03
U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio
Reuters · 04/06 08:06
Lipocine CEO Makes Bold Insider Move, Signaling Strong Confidence Ahead
TipRanks · 04/03 02:03
Lipocine CEO Mahesh V. Patel acquires shares worth $0.1 million
Reuters · 04/02 21:06
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results
Benzinga · 04/02 17:30
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 04/02 17:05
More
Webull provides a variety of real-time LPCN stock news. You can receive the latest news about Lipocine Inc through multiple platforms. This information may help you make smarter investment decisions.
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.